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Abstract
Background: It can be challenging for patients and clinicians to properly interpret a change in the
clinical condition after a treatment has been given. It is not known to which extent spontaneous
improvement, effect of placebo and effect of active interventions contribute to the observed
change from baseline, and we aimed at quantifying these contributions.
Methods: Systematic review and meta-analysis, based on a Cochrane review of the effect of
placebo interventions for all clinical conditions. We selected all trials that had randomised the
patients to three arms: no treatment, placebo and active intervention, and that had used an
outcome that was measured on a continuous scale or on a ranking scale. Clinical conditions that
had been studied in less than three trials were excluded.
Results: We analysed 37 trials (2900 patients) that covered 8 clinical conditions. The active
interventions were psychological in 17 trials, physical in 15 trials, and pharmacological in 5 trials.
Overall, across all conditions and interventions, there was a statistically significant change from
baseline in all three arms. The standardized mean difference (SMD) for change from baseline was -
0.24 (95% confidence interval -0.36 to -0.12) for no treatment, -0.44 (-0.61 to -0.28) for placebo,
and -1.01 (-1.16 to -0.86) for active treatment. Thus, on average, the relative contributions of
spontaneous improvement and of placebo to that of the active interventions were 24% and 20%,
respectively, but with some uncertainty, as indicated by the confidence intervals for the three
SMDs. The conditions that had the most pronounced spontaneous improvement were nausea
(45%), smoking (40%), depression (35%), phobia (34%) and acute pain (25%).
Conclusion: Spontaneous improvement and effect of placebo contributed importantly to the
observed treatment effect in actively treated patients, but the relative importance of these factors
differed according to clinical condition and intervention.
Background
It can be challenging for patients and clinicians to prop-
erly interpret a change in the clinical condition after a
treatment has been given. An improvement will often be
ascribed to the treatment, although at least two other fac-
tors often play a role.
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One factor is spontaneous improvement [1]. Many clini-
cal conditions are self-limiting, e.g. headache, acute low
back pain and the common cold, and most chronic dis-
ease symptoms fluctuate in intensity, e.g. rheumatoid
arthritis, chronic low back pain and psoriasis. Patients will
often seek medical attention when their symptoms are
worst, and they are most likely to be included in ran-
domised trials at this time. For the purpose of this paper,
we regarded regression to the mean effects as being part of
the spontaneous improvement. Regression to the mean
occurs, for example, when a patient can only be included
in a trial if the symptoms are worse than some threshold
value; for statistical reasons, the value will then likely be
lower at a later time [1,2].
The second factor is the effect of placebo. Patients may feel
reassured, change their expectation, or re-interpret their
symptoms once a treatment has been commenced. A
Cochrane systematic review did not find large effects of
placebo, but some effect in trials with patient-reported
continuous outcomes, especially pain [3-5].
We have not found any previous reviews of the three main
factors affecting the clinical course of patients included in
randomised clinical trials: spontaneous improvement,
effect of placebos and effect of active interventions (Fig.
1). We aimed at quantifying their relative contribution to
change from baseline in randomised trials.
Illustration of approximate contributions of spontaneous improvement and effect of placebo to the estimated effect of active  interventions Figure 1
Illustration of approximate contributions of spontaneous improvement and effect of placebo to the estimated 
effect of active interventions.
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Methods
The Cochrane review of the effect of placebo interventions
involved a thorough search for trials including a no-treat-
ment arm and a placebo arm. We selected all trials from
the updated Cochrane review of placebo interventions [5]
that had randomised the patients to three arms: no treat-
ment, placebo and active intervention, and that had used
an outcome that was measured on a continuous scale or
on a ranking scale. In order to permit analyses of separate
clinical conditions, we excluded conditions studied in less
than three trials.
Potentially eligible trial reports were read in full by one
author (LK), who made preliminary decisions on inclu-
sion and choice of outcome, and extracted the data. The
authors of the Cochrane review (AH and PCG) checked
the selections and the extracted data. Disagreements were
resolved by discussion.
In the Cochrane review, patient-reported outcomes were
preferred to observer-reported ones. For this study, we
selected the outcome that we found most relevant, disre-
garding whether it was patient- or observer-reported. We
made this decision by consensus; there was very little dis-
agreement. In seven cases, the chosen outcome was differ-
ent from that in the original review. An example is the
selection of the well-known observer-reported Bech-
Rafaelsen Melancholia Scale instead of the patient-
reported Befindlichkeits-Skala.
Data extraction was done using a pilot-tested chart. For
each trial, pre- and post-treatment means, standard devia-
tions and group sizes were extracted for the three arms.
Additional information extracted was: clinical condition,
acute or chronic problem, name and range of scale used,
and type of intervention (physical, pharmacological or
psychological).
Meta-analysis was done using Comprehensive Meta Anal-
ysis [computer program] version 2.2.030, July 2006.
Standardized mean differences (SMD) with 95% confi-
dence intervals were calculated for each trial. SMD is the
difference in means divided by the pooled standard devi-
ation. SMD was calculated as Hedges' g, with adjustment
for small sample bias. A negative SMD usually implies a
positive effect of the intervention, e.g. a lower pain score
means less pain. However, in four trials, a large clinical
score meant a beneficial effect, and we therefore changed
the sign of the SMD before the analysis in these cases.
Thus, a negative SMD in our analyses always means a ben-
eficial effect. When standard deviations were missing, we
used those from similar trials.
Due to the clinical diversity of the included patients, we
did not investigate one treatment effect, but rather the
mean of many different treatment effects. There was also
substantial methodological heterogeneity, e.g. some trials
did not have adequately concealed treatment allocation.
We therefore used a random effects model for the analy-
ses. The degree of heterogeneity was investigated with I2,
which describes the percentage of the variability in effect
estimates that is due to heterogeneity rather than sam-
pling error [6].
It was not straightforward how to do the analyses, as we
needed to compare the effects in the three groups with the
condition at baseline. We analyzed the three treatment
arms separately by comparing the post-treatment values
with the values at baseline. These data were paired, but we
analyzed them as if they were independent, as the presen-
tation of data in the articles did not allow paired analyses.
Thus, we accepted a moderate loss of statistical power by
handling the paired data as unpaired and assumed that
the effect of the ignored correlations between pre- and
post-intervention measurements was the same in all situ-
ations. It should be noted that this approach leads to over-
estimation of the sampling error, and therefore to
underestimation of the heterogeneity.
It was not possible to determine group sizes both pre- and
post-treatment for all trials. We therefore used post-treat-
ment sizes in the analyses, which has the advantage that
treatment arms with relatively more dropouts receive less
weight.
Ten trials had more than one active treatment. In the
meta-analysis, these were entered as separate treatment
arms and therefore contributed relatively more than trials
with only one active treatment arm. However, the same
would occur in trials with skewed randomisation ratios,
and overall, the numbers of patients contributing to the
results of the three treatment arms were not much differ-
ent.
Results
In- and exclusion of trials
There were 118 trials in the Cochrane review with contin-
uous outcome data. We excluded 61 trials: seven were
two-armed; in 27 trials, the clinical condition had been
studied in less than 3 trials; and 27 trials did not have a
baseline assessment. Almost all of the trials without a
baseline addressed acute conditions, for example acute
pain during a procedure. Though such trials often had pre-
treatment assessments they did not involve an assessment
of pain experienced during the procedure, or the treat-
ment was given before the painful procedure was initi-
ated. Thus, we identified 57 eligible trials. Data necessaryBMC Medical Research Methodology 2009, 9:1 http://www.biomedcentral.com/1471-2288/9/1
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for meta-analyses could not be obtained from 14 trials, so
we initially included 43 trials [7-49] (Fig. 2).
We found that the estimates for four hypertension trials
[46-49] were unreliable for our purpose. Three of the four
trials had run-in periods of 4 to 8 weeks before randomi-
sation, which eliminates the regression to the mean effect,
and the changes from baseline were therefore very small
and unstable.
We expected that the change from baseline in the no-treat-
ment arm and the placebo arm would covary from trial to
trial, so that when it was large in one arm, it also tended
to be large in the other. We verified this, but with two clear
outliers (Fig. 3, lower right corner). In one nausea trial
[10], the placebo therapy consisted of talks about the
child's daily life, which might have had a large reassuring
effect. In the other trial [33], the smoking rate was moni-
tored for one week before treatment in the placebo group,
but not in the no-treatment group.
Our overall results were very similar, whether or not we
excluded the four hypertension trials and the two outliers,
but we feel the results for nausea and smoking are more
reliable without the outliers. We report below the results
for 37 trials (2900 patients), after these six trials were
excluded.
Characteristics of included trials
The 37 trials covered eight different clinical conditions.
Most active interventions were of a psychological (17 tri-
als) or physical nature (15 trials); 5 trials were of drugs.
Typical psychological treatments were cognitive behav-
iour therapy and hypnosis, and physical treatment was
often acupuncture. Only 10 trials investigated conditions
defined by us as acute: depression [7-9], nausea [11,12],
and acute pain [13-17], while 27 trials investigated
chronic conditions: chronic pain [18-28], phobia [29-31],
smoking [32,34], obesity [35-39] and insomnia [40-45].
Duration of treatment was highly variable, ranging from a
few days to several months. The outcome was patient-
reported in 26 trials and observer-reported in 11 trials.
Statistical analyses
Overall, across all conditions and interventions, there was
a statistically significant change from baseline in all three
arms (Table 1). The SMD was -0.24 (95% confidence
interval -0.36 to -0.12, I2 = 25%) for no treatment, -0.44 (-
0.61 to -0.28, I2 = 57%) for placebo, and -1.01 (-1.16 to -
0.86, I2 = 57%) for active treatment. Thus, on average, the
relative contributions of spontaneous improvement and
of placebo to the change from baseline in the active inter-
vention groups were 24% (0.24/1.01) and 20% ((0.44-
0.24)/1.01), respectively (shown approximately in Fig. 1),
but with wide variation related to the studied clinical con-
ditions and interventions (Fig. 4). The most pronounced
spontaneous improvements, relative to the change from
baseline in the actively treated groups, were seen in nau-
sea 45%, smoking 40%, depression 35%, phobia 34%
and acute pain 25% (Fig. 4). When combining the influ-
ence of spontaneous remission and placebo, the similar
proportions were for nausea 73%, smoking 59%, depres-
sion 43%, phobia 74%, and acute pain 23% (Fig. 4).
The point estimates were very similar in trials with
patient-reported and observer-reported outcomes (Table
2) whereas trials involving acute conditions tended to
have larger improvements in all three arms compared
with trials involving chronic conditions (Table 3), as
expected.
Selection of trials for the review Figure 2
Selection of trials for the review.
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Discussion
We found that both the spontaneous improvement and
the effect of placebo contributed importantly to the
observed treatment effect in actively treated patients. As
noted above, we have not found other reviews that
describe the relative contributions of spontaneous remis-
sion and placebo to the improvement clinicians note
when they treat patients.
Our findings have two implications. First, they underline
that it is a fallacy when patients and clinicians interpret an
improvement that occurs after a treatment has been insti-
tuted as being caused by that treatment. In fact, we found
that, on average, only about half of that improvement
could be ascribed to the treatment in the trials we ana-
lysed.
Second, our findings show that it is wrong to describe the
effect that is observed in a placebo arm of a randomised
trial as the effect of placebo, as it includes the spontaneous
improvement that would also have occurred without
administration of a placebo [50]. This error is very com-
Change from baseline in the no-treatment and the placebo arms of the 37 analysed trials Figure 3
Change from baseline in the no-treatment and the placebo arms of the 37 analysed trials. The results are shown 
as standardized mean differences.
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mon. We did a full-text search on "placebo effect" on the
BMJ's website on 30 April 2008 and found the error in
90% of the articles, even in an obituary.
It is a limitation of our study that a quarter of the eligible
trials did not report the data necessary for our meta-anal-
yses. Furthermore, we had to use an unconventional
meta-analytic method but find it reassuring that the over-
all effect of placebo was -0.28, as this agrees closely with
our previous estimate of -0.24 in the Cochrane review [5]
where we used standard meta-analytic methods. We
would not expect more elaborate methods to yield results
that differ importantly from those we have reported here.
We considered other approaches and also did more tradi-
tional meta-analyses, comparing treatment arms within
each trial after treatment and calculating ratios between
the three arms before these ratios were pooled, but as the
denominators of the per trial ratios had a distribution that
crossed zero, these ratios were very unstable because of
"division almost by zero" effects. Furthermore, we could
not use this standard approach for the spontaneous
improvement, as this required comparison with baseline.
We did not try to convert our unpaired analyses into
paired ones, as this would have required estimations of
correlations that were likely to vary between diseases and
interventions.
The relative contributions of spontaneous improvement,
effects of placebo, and effects of active treatment to the
observed change from baseline varied considerably. The
eight clinical conditions we analysed were either psychiat-
ric diseases (depression and phobia), involved a high
degree of patient cooperation (smoking and obesity) or
involved subjective outcomes (acute and chronic pain,
nausea, and insomnia); and the interventions were mostly
non-pharmacological. It seems likely that spontaneous
improvement is more important in trials that include
patients with high symptom scores and that do not imple-
ment a placebo run-in period, particularly as the regres-
sion to the mean is likely to be more pronounced in such
settings.
Table 1: Standardized mean differences (SMD) for changes from baseline in the three treatment arms separately.
No. of patients No. of treatment arms SMD (95% confidence interval) I2 (%)
No treatment Overall 978 37 -0.24 (-0.36 to -0.12) 25
Depression 42 3 -0.44 (-1.27 to 0.39) 70
Nausea 60 2 -0.63 (-0.97 to -0.30) 0
Pain – acute 63 5 -0.53 (-1.03 to -0.02) 49
Pain – chronic 265 11 -0.10 (-0.27 to 0.06) 0
Phobia 28 3 -0.39 (-0.91 to 0.12) 3
Smoking 391 2 -0.40 (-0.54 to 0.26) 0
Obesity 46 5 -0.02 (-0.41 to 0.36) 0
Insomnia 83 6 0.03 (-0.27 to 0.33) 0
Placebo Overall 849 37 -0.44 (-0.61 to -0.28) 57
Depression 44 3 -0.54 (-1.53 to 0.44) 80
Nausea 59 2 -1.02 (-1.37 to -0.66) 0
Pain – acute 62 5 -0.48 (-1.03 to 0.07) 57
Pain – chronic 241 11 -0.32 (-0.59 to -0.04) 54
Phobia 32 3 -0.85 (-1.35 to -0.36) 0
Smoking 272 2 -0.58 (-1.37 to 0.22) 78
Obesity 58 5 -0.17 (-0.52 to 0.18) 0
Insomnia 81 6 -0.31 (-0.61 to 0.00) 0
Active treatment Overall 1073 52 -1.01 (-1.16 to -0.86) 57
Depression 49 3 -1.27 (-1.91 to -0.62) 53
Nausea 60 2 -1.39 (-2.58 to -0.23) 87
Pain – acute 61 5 -2.12 (-3.01 to -1.24) 73
Pain – chronic 373 17 -0.81 (-1.03 to -0.59) 52
Phobia 48 5 -1.15 (-1.67 to -0.63) 33
Smoking 275 3 -0.99 (-1.16 to -0.81) 0
Obesity 61 5 -0.53 (-1.23 to 0.17) 73
Insomnia 146 12 -1.06 (-1.30 to -0.82) 0BMC Medical Research Methodology 2009, 9:1 http://www.biomedcentral.com/1471-2288/9/1
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Relative contributions of the spontaneous improvement, effect of placebo, and effect of active treatment to the change from  baseline seen in the actively treated group Figure 4
Relative contributions of the spontaneous improvement, effect of placebo, and effect of active treatment to 
the change from baseline seen in the actively treated group.
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Table 2: Standardized mean differences (SMD) for changes from baseline grouped by patient- and observer-reported outcome.
No. of treatment arms SMD (95% confidence interval) I2 (%)
No treatment
Observer-reported 11 -0.28 (-0.56 to -0.01) 20
Patient-reported 26 -0.22 (-0.36 to -0.09) 30
Placebo
Observer-reported 11 -0.50 (-0.81 to -0.20) 40
Patient-reported 26 -0.42 (-0.62 to -0.22) 63
Active treatment
Observer-reported 16 -0.92 (-1.22 to -0.62) 56
Patient-reported 36 -1.04 (-1.22 to -0.87) 59BMC Medical Research Methodology 2009, 9:1 http://www.biomedcentral.com/1471-2288/9/1
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Our Cochrane review suggested that the effect of placebos
is smaller when imitating pharmacological interventions
and when outcomes are observer-reported [3-5]. It is
therefore likely that the effect of placebo is comparatively
less important in drug trials and in trials with observer-
reported outcomes. The Cochrane review found a small
effect of placebo on pain, which we reproduced in this
review for chronic pain, but not for acute pain, possibly
because we were unable to include many acute pain trials
that provided no baseline data.
The active interventions we included seemed to be quite
effective, which is surprising, as most of them were uncon-
ventional, and as many trials involved acupuncture. We
recently did a systematic review of three-armed acupunc-
ture trials and found a small analgesic effect of acupunc-
ture, compared to placebo acupuncture, that seems to lack
clinical relevance and could not be clearly distinguished
from bias [51]. The apparent effects we noted of active
treatments may therefore to some degree reflect bias, e.g.
related to unconcealed allocation of patients and unsuc-
cessful blinding.
A major problem related to the interpretation of the out-
comes in no-treatment and placebo groups is the lack of
blinding. Blinding is important to reduce reporting bias in
experiments with subjective outcomes [52], but it is not
possible to blind patients who receive no treatment. The
lack of blinding favours placebo [52], as patients were
often blinded with respect to placebo and active treat-
ment. Patients in the placebo group may think they
receive active treatment, or they may tend to please their
doctors by exaggerating the improvement, and conversely,
patients in the no-treatment group may tend to view their
experiences more negatively, as they may feel deprived of
treatment.
Conclusion
We conclude that both the spontaneous improvement
and the effect of placebo contribute importantly to the
observed treatment effect in actively treated patients, and
that the relative importance of these factors differ accord-
ing to clinical condition and intervention.
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